Any feedback?
Literature summary extracted from
- Enzyme replacement therapy for MorquioA: an active recombinant N-acetylgalactosamine-6-sulfate sulfatase produced in Escherichia coli BL21 (2010), J. Ind. Microbiol. Biotechnol., 37, 1193-1201.
Cloned(Commentary)
| EC Number | Cloned (Comment) | Organism |
|---|---|---|
| 3.1.6.4 | recombinant enzyme expression in Escherichia coli strain BL21 in both soluble and inclusion bodies fractions, rGALNS amounts in inclusion bodies fraction are up to 17fold higher than those observed in the soluble fraction, method optimization, effect of aeration and agitation at bench scale, detailed overview | Homo sapiens |
Organism
| EC Number | Organism | UniProt | Comment | Textmining |
|---|---|---|---|---|
| 3.1.6.4 | Homo sapiens | P34059 | - |
- |
Synonyms
| EC Number | Synonyms | Comment | Organism |
|---|---|---|---|
| 3.1.6.4 | GALNS | - |
Homo sapiens |
General Information
| EC Number | General Information | Comment | Organism |
|---|---|---|---|
| 3.1.6.4 | malfunction | mucopolysaccharidosis IVA, MPS IVA, is an autosomal recessive disorder caused by N-acetylgalactosamine-6-sulfate sulfatase deficiency and leading to lysosomal accumulation of the glycosaminoglycans keratan sulfate and chondroitin-6-sulfate | Homo sapiens |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
